Unlike therapies that can deplete the immune system, mezigdomide enhances T-cell number and function. This unique immune-enhancing property makes it a promising agent to use before, or in combination with, immunotherapies like CAR-T to overcome resistance and improve outcomes in highly refractory patients.

Unlike IMiDs (lenalidomide) which only close the Cereblon E3 ligase complex by 15-20%, mezigdemide achieves 100% closure. This leads to more robust degradation of key proteins, causing powerful direct myeloma cell destruction and enhanced immune activation, earning it the nickname 'CAR T in a pill.'

Lenalidomide has a unique off-target effect on C1K alpha which clonally selects for p53 mutated cells, increasing second cancer risk. Preclinical data clearly show that CELMoDs like iberdomide and mezigdomide do not share this mechanism, offering a significant potential safety advantage over the older IMiD.

An expert who initially viewed CELMoDs as incremental improvements now considers them fundamentally different. The new litmus test for future myeloma trials will be tracking prior patient exposure to CELMoDs like iberdomide, just as they track prior IMiD exposure today, cementing their status as a distinct therapeutic category.

In a heavily pretreated population, mezigdemide plus dexamethasone achieved a 50% response rate in patients refractory to prior BCMA-based approaches, including antibody-drug conjugates, bispecifics, and CAR T-cell therapy. This demonstrates a distinct mechanism that can overcome resistance to the latest immunotherapies.

Unlike IMiDs, which only partially engage the target, CELMoDs like iberdomide are larger molecules that fully close the cereblon E3 ligase pocket. This maximizes degradation of target proteins Ikaros and Aiolos, leading to greater potency and what is described as "hitting the death star" of the myeloma cell.

New oral CELMoDs like mezigdemide show a surprising ability to make previously ineffective drugs, like bortezomib and carfilzomib, work again. This resensitization mechanism offers a powerful strategy to recycle older therapies, expanding options for heavily pretreated patients.

Mezigdomide is considered one of the most active oral agents against extramedullary disease (EMD). Its molecular structure was specifically engineered to optimize tissue penetration, addressing a significant clinical challenge where myeloma grows outside the bone marrow in heavily pretreated patients.

Beyond their direct anti-myeloma effects, CELMoDs potently activate the immune system. This positions them as ideal partners for immunotherapies like CAR T and bispecifics, with the potential to restore immune function and overcome resistance to T-cell redirecting therapies.